Month: March 2015

What are your views on Gene Therapy?

Posted on Updated on

We used to think that our fate was in our stars, but now we know that, in large measure, our fate is in our genes, “quotes James Watson.

This fate that Watson is talking about is contained in our genes, and deals with a new technique, GENE THERAPY.

gdfgGene therapy is an innovative way to fix genetic problem from the source. By adding a corrected copy of a defective gene, gene therapy promises to help diseased tissues and organs work properly. This approach is different from traditional drug-based approaches, which may treat symptoms but not the underlying genetic problems.

The treatment sounds magical, but the complexity of designing and delivering arises. The safety issues slowed the progress, following events like death of Jess Gelsinger, who died in 1999 just weeks after receiving an experimental gene therapy in a clinical trial being conducted by the University of Pennsylvania.

Although gene therapy is a promising treatment option for a number of diseases, the technique remains risky and is still under study to make sure that it will be safe and effective.

Also some genetic disorders are rare in nature affecting 1 in million. For such patients, Gene therapy can be a miracle but high cost of developing a treatment can make it unappealing for the pharmaceutical companies. With a limited number of patients to recover those expenses from, developers may never earn money from treating such rare genetic disorders. And some patients may never be able to afford them.

The first milestone in gene therapy, Gendicine, developed by Shenzhen SiBiono GeneTech was approved in China in 2003 for the treatment of head and neck cancers and the biggest watershed moment was Glybera, a gene therapy for lipoprotein lipase deficiency, launched in Germany at a price of more than 1 million euros ($1.1 million).

Meanwhile, companies like bluebird bio and Spark Therapeutics generated impressive clinical data with programmes of their own.

The success has generated renewed interest from both private and public equity investors as well as pharmaceutical companies, such as Bayer and Sanofi, which have willingly provided much-needed resources to companies working in the field in the form of financing and partnerships, helping to drive what could turn out to be a virtuous circle of success.

DelveInsight Gene Therapy Reports

DelveInsight’s Reports have already established a reputation of offering the affordable and comprehensive industry coverage and “on-the-ground” analysis in virtually every region of the world. These reports provide complete information for over 300 gene therapies which are in the pipeline for various therapy areas like; Oncology, Genitourinary, Dermatology, Central nervous system, Genetic Disorders, Hematological disorders, Metabolic disorders, Ophthalmology, Cardiovascular disease, Respiratory , Immunology, and many more…

DelveInsight’s Gene Therapy Reports cover the entire gene therapy market scenario including technology assessments, licensing opportunities, collaborations, market trends, pipeline coverage and competitive landscape. The report essentially provides DelveInsight’s proprietary market and pipeline analytics which identifies the front runners of all therapeutic areas. It also identifies the potential market movers and future regulatory landscape. These reports are designed to provide the clients with the means to out produce their competitors by developing a product that makes history.

For more info on Gene Therapy Reports for various Therapeutic areas contact us at: info@delveinsight.com.

By Rashi Aggarwal, Associate Analyst, DelveInsight

Please give your views on Gene Therapy and lets discuss about its potential in the market.

Antibody-Drug Conjugate Market Outlook, 2015 Report in Market Now!

Posted on Updated on

assdd

Launch of DelveInsight’s Antibody-Drug Conjugate Report

DelveInsight’s Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. The Report has covered the 264 Antibody-drug conjugates profile which gives cdadadadadadore information of the targets, mechanism of action, development partner, Technology partner, monoclonal antibody used, linker used and cytotoxic drug with the descriptive information of the technologies. The Report also provides the assessment of the company’s undergone collaborations for technology and monoclonal antibody and also gives insights over the pre-clinical and clinical data. The Report has also assessed the ADCs on geographical distribution based on the country and region.

Around 253 ADCs in Oncology
Antibody-Drug Conjugates are getting researched mostly for cancers. Cancer being the highest research area, there are 253 ADCs currently in pipeline. There are other companies which is also researching the ADC for different therapeutic areas like dermatology, immunology, women’s health, gastrointestinal and ophthalmology.

Four Potential ADCs in Phase III Pipeline 

Companies are trying its already marketed ADC for different combinations and for different indications like Roche, Seattle Genetics conducting total 9 trials on their ADCs trastzumab emantisine and Brentuximab Vedotin. There are two new ADCs AstraZeneca’s Moxetumomab Pasudotox and Pfizer’s Inotuzumab Ozogamicin for Relapsed/ Refractory Hairy Cell Leukemia and Acute Lymphoblastic Leukemia respectively.
Report Pricing
Single User License:  3500 USD
Site License: 7000 USD
Global License: 10500 USD
For more information email us at info@delveinsight.com or visit us at http://www.delveinsight.com
Ask for Sample Pages now!

Next Generation Antibody-Drug Conjugate Therapeutics and its Market

Posted on Updated on

Antibody-Drug Conjugates-A Big Boom!

Therapeutics developed to create innovative medicines based on the use of new and improved antibodies is the next generation cure for the treatment of various diseases. In past decade, the antibody drug conjugates have emerged out as the active areas of many biopharmaceutical companies and contract manufacturing firms. With recent approvals of two ADC, Adcetris and Kadcyla and many in clinical pipeline, the ADC development has become one of the most attractive and exciting new class of drugs especially in oncology therapeutics. The present two ADC which are market have been approved by both US Food and Drug Administration (FDA) and the European Medicine Agency (EMA).

These antibody drug conjugates have increased selectivity and enhanced efficacy which attracts the developers with real promise and massive potential of becoming a huge hit as monoclonal antibodies itself. It is composed by linking an antibody with the cytotoxic drug. A good target selection, its internalization rate and optimization of each part plays a vital role. Although when it comes to efficacy a lot of research is been done into the targeting of the ADCs. The internalization also depends on the drug payload with novel mechanism of action. It is highly important to consider that if multiple toxins are used it can be either better or could lead to more resistance. Some of the promising payloads are Auristatin, Pyrrolobenzodiazapines (PBDs) and Maytinsinoid. The ADC development future is much dependent on the site specific conjugation as better site specific methods will lead to improved drug to antibody ratio and shelf life. Have a look at Top 5 Companies and their ADCs in pipeline

ggfgf

Technological advancements, success of monoclonal antibodies (MAb) and increasing demands of biologics drugs in globally for the treatment of chronic diseases are prime factors to drive this market. In October 2013, Roche announced that it plans to invest 800 million Swiss francs in global biologic medicine manufacturing network. The company is coming up with combination product with Kadcyla in clinical trials. With linker technology advances in antibody therapies, raise in healthcare expenditure and huge government initiatives, North America has the largest market for the next generation of antibody based therapeutics followed by Europe. With growing demographics and economics, demand of better healthcare facilities, increasing incidence of chronic diseases and growing R&D activities one can expect that Asia will also observe a high growth rate in coming years.

A trend frequently observed in ADC market is the increasing number of collaborations and partnerships particularly for the technology advantages and rise in number of mergers and acquisitions. MedImmune subsidiary of AstraZeneca are jointly developing two therapies with ADC Therapeutics. Spirogen are in partnership with ADC therapeutics for several oncology indications. Despite of increasing number of companies getting into collaboration, there are few top challenges identified in common such as optimization of multi-parameters, lack of proof of concept with right characteristics selection, scale up of processes, drug to antibody ratio, lack of regulatory guidance and high cost of research and development with further commercialization. ADC half life and drug stability are also important factors which depend on the better understanding of PK and related toxicity. With the upcoming of many ADC technologies under exploration, the challenges and competition are rising. Better communication networks and collaborations both internally in a company and externally will solve a number of issues as within a company itself different components of ADC are dealt with different departments. With many organizations looking forward to this exciting new class of drug, the major focus should lie in the early stage discovery and opportunities. Currently the major players in the market associated with ADCs are Seattle Genetics, MedImmune, F. Hoffmann-La Roche Ltd, ImmunoGen, Amgen and Pfizer. The contract manufacturing organizations also play vital role like Piramal, Lonza and SAFC invests for the production of ADC.

Written by Tarun Jain, Associate Analyst, DelveInsight

For more information contact DelveInsight at info@delveinsight.com

Coming Soon! DelveInsight New Report Antibody-Drug Conjugate Global Market and Pipeline Outlook, 2015 (For Sample Pages, mail us at info@delveinsight.com)

http://www.prlog.org/12434185-coming-soon-delveinsight-new-report-antibody-drug-conjugate-global-market-and-pipeline-outlook-2015.html

Antibody-Drug Conjugates Market Outlook, 2015 Report

Posted on Updated on

dasds

264 Antibody-Drug Conjugates in Pipeline!!!!

Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. Billions of dollars are spent on the chemotherapy treatments annually. The ongoing research on this therapy will replace the chemotherapeutics treatments in the near future thereby reducing its toxic side effects. Different Biotechnology companies and Pharma Companies are collaborating in all area of ADCs like linker technology, antibody production and conjugation process. There are total 264 ADCs in pipeline and two are marketed.

 

Around 253 ADCs in Oncologydsad

Antibody-Drug Conjugates are getting researched mostly for cancers. Cancer being the highest research area, there are 253 ADCs currently in pipeline. There are other companies which is also researching the ADC for different therapeutic areas like dermatology, immunology, women’s health, gastrointestinal and ophthalmology.

 

Four Potential ADCs in Phase III Pipeline

Companies are trying its already marketed ADC for different combinations and fofffr different indications like Roche, Seattle Genetics conducting total 9 trials on their ADCs trastzumab emantisine and Brentuximab Vedotin. There are two new ADCs AstraZeneca’s Moxetumomab Pasudotox and Pfizer’s Inotuzumab Ozogamicin for Relapsed/ Refractory Hairy Cell Leukemia and Acute Lymphoblastic Leukemia respectively.

 

 

DelveInsight’s Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. The Report has covered the 264 Antibody-drug conjugates profile which gives core information of the targets, mechanism of action, development partner, Technology partner, monoclonal antibody used, linker used and cytotoxic drug with the descriptive information of the technologies. The Report also provides the assessment of the company’s undergone collaborations for technology and monoclonal antibody and also gives insights over the pre-clinical and clinical data. The Report has also assessed the ADCs on geographical distribution based on the country and region.

Pre-Launch Offer!!

dsasdas

We are giving a limited period offer of USD 500 off on Antibody-Drug Conjugate Global Market and Pipeline Outlook, 2015.

 

 

Pricing

Single-User License Site License Global License
USD 3500 USD 7000 USD 10500

Ask for Sample Pages now!!!

For Sample Pages, please write to us at info@delveinsight.com

For more information about the company visit DelveInsight website

DelveInsight Hiring!!!!

Posted on Updated on

logo 1

Looking for Passionate Candidates

Mail your updated Resume to careers@delveinsight.com 

www.delveinsight.com

Twitter, Facebook, LinkedIn

JOB DESCRIPTION

Profile Offered: Associate Analyst

Education: M. Pharma/M.tech Biotech

Roles and Responsibilities:

  • Conduct market research through primary and secondary sources according to the client needs
  • Maintain knowledge databases and making new databases.
  • Compile, analyze and present data in the form of reports to clients.
  • Responsible for strategy development, weekly updates and project delivery.
  • Customer centric problem solving skills within their own realm of expertise.

Core Competencies

  • Strong verbal and oral communication skills
  • Team player and excellent interpersonal skills
  • Logical and creative thinker with enthusiasm and a desire to get involved

Technical Skills

  • Sound subject knowledge
  • Ability to work on diverse technical domains (related to the field of life sciences)

………………………………………………………………………………………….

Profile Offered: Business Development Executive

Education: B. Pharma/B.Tech Biotech/MBA/B.Sc

Roles and Responsibilities:

  • The Business Development role is responsible for building sales pipeline and creating, negotiating and closing licensing, redistribution and partnership agreements or contracts in collaboration with in-house legal and commercial teams and generating revenue to the organization.
  • Develop and maintain a robust network of industry contacts to facilitate business development activity and raise the Access profile in the market
  • Develop and leverage strong relationships with key Pharma companies in order to fully evangelize our portfolio of offerings
  • To achieve the goals, we expect that the individual will represent DelveInsight Indices at industry events and conferences, potentially speak at them, and produce thought leadership materials.
  • Develop and follow up leads – religiously
  • Appointment fixing
  • Ability to pass through reception and reach the right point of contact in one call
  • Build effective, strategic and productive business relationships with key decision makers within the client organization.
  • Talk to international customers on daily basis

 

About Us

DelveInsight is a Business Consultant company and serve as a Knowledge partner across the value chain of Pharmaceutical Industry. DelveInsight provides cutting-edge market and pipeline analysis and also an API intelligence knowledge partner for the Pharma and biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios and companies. We combine industry expertise with innovation by collecting, analyzing and communicating to deliver critical information to leading decision makers in the Approved drugs market, Active Pharmaceutical (API) market, Generic market and Drug’s research and development. We help Drug developing companies, Generics and API manufacturing companies to strategize and identify the right thrust areas and potential customers for their existing and new products.

At DelveInsight, we believe what we do matters. We are passionate about our work, inspired by the impact it has on our business and our customers. As a team, we believe in winning as one – collaborating to reach shared goals, and developing through challenging and meaningful experiences. The pharmaceuticals market is in its growth stage and we are uniquely positioned to successfully endeavour the dimensions of the fast growing market by providing cutting-edge market and pipeline information, to our clients.

 

Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy

Posted on

Antibody–drug conjugates (ADCs), a new weapon of 21st Century for fighting Cancer

Traditional cancer chemotherapy was having harsh side effects and also leads to systemic toxicity. The approach was also referred to as the carpet-bombing strategy for fighting cancer. Traditional chemotherapy does not discriminate between cancer cells and other fast dividing cells which are common in the body. In the recent years, new technology has emerged to fight cancer; Antibody–drug conjugates (ADCs). ADCs use antibodies to deliver a potent cytotoxic compound selectively to tumor cells, thus improving the therapeutic index of chemotherapeutic agents. The type of antibody used to create the drug is selected based upon unique biomarkers found on the cancer cells to be targeted. This approach has lesser side effects.

ADC

 

Antibody-Drug Conjugates (ADCs) is an emerging concept in cancer therapy with the goal of reducing the effects of chemotherapy on healthy cells.

ADCs combine three components to target cancer in a new way:

  1. The antibody which targets and binds to specific receptors on the surface of cells.
  2. The chemotherapy/cytotoxic drugis delivered directly to cancer cells and destroy them once absorbed.
  3. The linker binds the antibody to chemotherapy so that the chemotherapy is not released until it reaches cancer cells.

ADCs are designed to be stable in circulation and to effect intracellular drug release following antigen-specific binding and internalization of the ADC.

Recent efforts in oncology have focused on identifying drugs with improved selectivity for malignant versus normal cell as a means to improve both the efficacy and tolerability of cancer treatment. There are 180+ ADCs undergoing development and 80+ ADCs in clinical evaluations for oncology.

dsad

ADCs are being developed to target Breast Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Multiple Myeloma, B-cell malignancies, and Acute myeloid Leukemia (AML).

The recent approval of two ADCs, brentuximab vedotin and ado-trastuzumab emtansine, for cancer treatment has spurred tremendous research interest in this field.

ADCs are part of a specialized subset of highly potent APIs. Although challenges remain, recent clinical success has generated intense interest in this therapeutic class. Ongoing efforts to address the challenges will continue to broaden the impact of ADCs as targeted therapeutics for the treatment of cancer and potentially other diseases.

This technically challenging type of therapy combines innovations from biotechnology and chemistry to form a new class of highly potent biopharmaceutical drugs.

For more information on Antibody Drug Conjugates, please contact us at info@delveinsight.com

Written by Rashi Agarwal, Associate Analyst, DelveInsight